IRVINE, CA -- (Marketwire) -- 04/25/12 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that it had filed a lawsuit in the Dusseldorf Patent Litigation Court asserting that one of its European competitors is infringing on BIOLASE European Patent EP 1 560 470, which relates to the output of optical energy of lasers. The lawsuit, filed on April 13, 2012, seeks both cash damages and injunctive relief from the courts. The lawsuit was filed after failed attempts were made to create an amicable business arrangement between the two companies.
Federico Pignatelli, Chairman and CEO, said, "BIOLASE is committed to asserting its rights in its extensive patent portfolio in the U.S. and internationally. With more than 280 U.S. and international patents and patents pending, the Company has invested heavily in its intellectual property portfolio for laser dentistry and other medical fields. We will not tolerate what we believe to be infringement of our patents, and we will be very aggressive in protecting our rights."
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate 285 patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 19,000 lasers among 16,000 customers. Other products under development address ophthalmology and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by BIOLASE management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and BIOLASE undertakes no obligation to update such statements.
For further information, please contact:
Allen & Caron